Table 4. Analysis of normalized cycle length during drug application.

Group A				Group B
Condition	n	Mean	S.E.M	Condition	n	Mean	S.E.M	P
HH St. 26 Baseline	110	1.000	0.005	HH St.26 10 μM Scopolamine	92	0.750	0.019	<0.0001
HH St. 26 Baseline	28	1.000	0.013	HH St. 26 10 μM PTX	11	0.928	0.013	0.003
HH St. 30 Baseline	90	1.000	0.01	HH St. 30 2 μM Scopolamine	88	0.689	0.021	<0.0001
HH St. 30 Baseline	86	1.000	0.004	HH St. 30 10 μM Scopolamine	81	0.901	0.004	<0.0001
HH St. 30 Baseline	69	1.000	0.003	HH St. 30 10 μM PTX	64	0.877	0.043	0.005

n = number of neurons examined; ≥3 embryos examined per condition.